Pfizer (PFE) Revenue — Quarter Ended Jun 30, 2024
Revenue for the quarter declined sequentially but rose compared to the same period last year. The company indicated that operating cash flows were lower in the first half and that revenue is expected to be more heavily weighted to the fourth quarter due to product seasonality.
Key takeaway
Quarter ended Jun 30, 2024 · FY2024 Q2
Revenue for the quarter declined sequentially but rose compared to the same period last year. The company indicated that operating cash flows were lower in the first half and that revenue is expected to be more heavily weighted to the fourth quarter due to product seasonality.
Financial snapshot
Reported revenue, sequential change, year-over-year change, and trailing four-quarter revenue.
Quarter revenue
$13.3B
Revenue reported for this quarter.
Quarter-over-quarter
-10.7%
Change from the immediately preceding quarter.
Year-over-year
+2.1%
Change from the comparable year-ago quarter.
Trailing four quarters
$56.2B
Sum of the latest four reported quarters.
Quarterly revenue trend
The latest four reported quarters with year-over-year comparisons.
| Period ended | Revenue | Year-over-year change |
|---|---|---|
| Oct 1, 2023 | $13.5B | -40.4% |
| Dec 31, 2023 | $14.6B | -42.0% |
| Mar 31, 2024 | $14.9B | -19.5% |
| Jun 30, 2024 | $13.3B | +2.1% |
Revenue performance
The reported quarter's revenue decreased from the immediately preceding quarter, while showing an increase relative to the same quarter one year earlier.
Quarterly comparison
Compared to the prior quarter, revenue was lower, reflecting a sequential decline. In contrast, compared to the same quarter a year ago, revenue was higher, marking a year-over-year improvement.
What to watch
Monitor the company's cash flow timing and the expected fourth-quarter revenue concentration due to seasonality.